Clinical value and potential mechanisms of BUB1B up-regulation in nasopharyngeal carcinoma

Qin, Li-Ting; Huang, Si-Wei; Huang, Zhi‐Guang; Dang, Yi‐Wu; Fang, Ye‐Ying; He, Juan; Niu, Yi‐Tong; Lin, Cai‐Xing; Wu, Ji‐Yun; Wei, Zhu‐Xin

doi:10.1186/s12920-022-01412-8

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Qin et al. also found that BUB1B is highly expressed in nasopharyngeal carcinoma and that BUB1B can promote tumor progression by regulating the cell cycle ( 34 ). Zhu et al.…”

Section: Resultsmentioning

confidence: 99%

“…Zeng et al found that the expression level of NDC80 in human glioblastoma cells was significantly higher than that in normal cells and that NDC80 could promote the proliferation and invasion of human glioblastoma cells (33). Qin et al also found that BUB1B is highly expressed in nasopharyngeal carcinoma and that BUB1B can promote tumor progression by regulating the cell cycle (34). Zhu et al found that BUB1 promoted the proliferation of liver cancer cells by activating the phosphorylation of SMAD2 (35).…”

Section: Results Mrna Level and Prognostic Value Of The Ska Familymentioning

confidence: 99%

See 1 more Smart Citation

Immunological role and prognostic value of the SKA family in pan-cancer analysis

Huang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundThe spindle and kinetochore associated (SKA) complex, which plays important roles in proper chromosome segregation during mitosis by maintaining the stabilization of kinetochore-spindle microtubule attachment during mitosis, has recently been reported to exert regulatory effects on the initiation and progression of various human cancer types. Nevertheless, the prognostic significance and immune infiltration of the SKA family across cancers have not been well elucidated.MethodsUsing data from three large public datasets, including The Cancer Genome Atlas, Genotype-Tissue Expression, and Gene Expression Omnibus databases, a novel scoring system (termed the SKA score) was developed to quantify the SKA family level across cancers. We then evaluated the prognostic impact of the SKA score on survival and assessed the effect of the SKA score on immunotherapy at the pan-cancer level using multiomics bioinformatic analyses. The correlation of the SKA score and the tumor microenvironment (TME) was also explored in depth. Potential small molecular compounds and chemotherapeutic agents were assessed by CTRP and GDSC analyses. Immunohistochemistry was performed to verify the expression of the SKA family genes.ResultsOur results demonstrated a close correlation between the SKA score and tumor development and prognosis in multiple cancers. The SKA score was positively related to cell cycle pathways and DNA replication across cancers, such as E2F targets, the G2M checkpoint, MYC targets V1/V2, mitotic spindles and DNA repair. Additionally, the SKA score was negatively related to the infiltration of various immune cells with antitumor effects in the TME. In addition, the potential value of the SKA score was identified to predict immunotherapy response for melanoma and bladder cancer. We also demonstrated a correlation between SKA1/2/3 and the response to drug treatment across cancers and the promising potential of the SKA complex and its genes as therapeutic targets in cancer. Immunohistochemistry demonstrated that the expression differences of SKA1/2/3 were significant between the breast cancer group and the paracancerous group.ConclusionThe SKA score plays a critical role in 33 cancer types and is highly related to tumor prognosis. Patients with elevated SKA scores have a clear immunosuppressive TME. The SKA score may serve as a predictor for patients receiving anti-PD-1/L1 therapy.

show abstract

“…Qin et al. also found that BUB1B is highly expressed in nasopharyngeal carcinoma and that BUB1B can promote tumor progression by regulating the cell cycle ( 34 ). Zhu et al.…”

Section: Resultsmentioning

confidence: 99%

Section: Results Mrna Level and Prognostic Value Of The Ska Familymentioning

confidence: 99%

Immunological role and prognostic value of the SKA family in pan-cancer analysis

Huang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Integrative Bioinformatics Analysis for Targeting Hub Genes in Hepatocellular Carcinoma Treatment

Gudivada,

Amajala

2025

View full text Add to dashboard Cite

Background: The damage in the liver and hepatocytes is where the primary liver cancer begins, and this is referred to as Hepatocellular Carcinoma (HCC). One of the best methods for detecting changes in gene expression of hepatocellular carcinoma is through bioinformatics approaches. Objective: This study aimed to identify potential drug target(s) hubs mediating HCC progression using computational approaches through gene expression and protein-protein interaction datasets. Methodology: Four datasets related to HCC were acquired from the GEO database, and Differentially Expressed Genes (DEGs) were identified. Using Evenn, the common genes were chosen. Using the Fun Rich tool, functional associations among the genes were identified. Further, protein-protein interaction networks were predicted using STRING, and hub genes were identified using Cytoscape. The selected hub genes were subjected to GEPIA and Shiny GO analysis for survival analysis and functional enrichment studies for the identified hub genes. The up-regulating genes were further studied for immunohistopathological studies using HPA to identify gene/protein expression in normal vs HCC conditions. Drug Bank and Drug Gene Interaction Database were employed to find the reported drug status and targets. Finally, STITCH was performed to identify the functional association between the drugs and the identified hub genes. Results: The GEO2R analysis for the considered datasets identified 735 upregulating and 284 downregulating DEGs. Functional gene associations were identified through the Fun Rich tool. Further, PPIN network analysis was performed using STRING. A comparative study was carried out between the experimental evidence and the other seven data evidence in STRING, revealing that most proteins in the network were involved in protein-protein interactions. Further, through Cytoscape plugins, the ranking of the genes was analyzed, and densely connected regions were identified, resulting in the selection of the top 20 hub genes involved in HCC pathogenesis. The identified hub genes were: KIF2C, CDK1, TPX2, CEP55, MELK, TTK, BUB1, NCAPG, ASPM, KIF11, CCNA2, HMMR, BUB1B, TOP2A, CENPF, KIF20A, NUSAP1, DLGAP5, PBK, and CCNB2. Further, GEPIA and Shiny GO analyses provided insights into survival ratios and functional enrichment studied for the hub genes. The HPA database studies further found that upregulating genes were involved in changes in protein expression in Normal vs HCC tissues. These findings indicated that hub genes were certainly involved in the progression of HCC. STITCH database studies uncovered that existing drug molecules, including sorafenib, regorafenib, cabozantinib, and lenvatinib, could be used as leads to identify novel drugs, and identified hub genes could also be considered as potential and promising drug targets as they are involved in the gene-chemical interaction networks. Conclusion: The present study involved various integrated bioinformatics approaches, analyzing gene expression and protein-protein interaction datasets, resulting in the identification of 20 topranked hubs involved in the progression of HCC. They are KIF2C, CDK1, TPX2, CEP55, MELK, TTK, BUB1, NCAPG, ASPM, KIF11, CCNA2, HMMR, BUB1B, TOP2A, CENPF, KIF20A, NUSAP1, DLGAP5, PBK, and CCNB2. Gene-chemical interaction network studies uncovered that existing drug molecules, including sorafenib, regorafenib, cabozantinib, and lenvatinib, can be used as leads to identify novel drugs, and the identified hub genes can be promising drug targets. The current study underscores the significance of targeting these hub genes and utilizing existing molecules to generate new molecules to combat liver cancer effectively and can be further explored in terms of drug discovery research to develop treatments for HCC.

show abstract

Comprehensively analyzing the genetic alterations, and identifying key genes in ovarian cancer

TANG¹,

ATIQ²,

MAHNOOR³

et al. 2023

Oncology Research

View full text Add to dashboard Cite

Clinical value and potential mechanisms of BUB1B up-regulation in nasopharyngeal carcinoma

Cited by 3 publications

References 35 publications

Immunological role and prognostic value of the SKA family in pan-cancer analysis

Immunological role and prognostic value of the SKA family in pan-cancer analysis

Integrative Bioinformatics Analysis for Targeting Hub Genes in Hepatocellular Carcinoma Treatment

Comprehensively analyzing the genetic alterations, and identifying key genes in ovarian cancer

Contact Info

Product

Resources

About